Sickle cell gene therapies offer new hope, but access remains a major challenge

A finance story from the U.S., reported by CNBC Top News.

Finance · the U.S. · October 16, 2026

From CNBC Top News

FDA-approved gene therapies for sickle cell disease offer a chance to help patients, but factors including cost and access have slowed their use.

Reported by CNBC Top News, October 16, 2026. Read the full story at CNBC Top News →

More finance from the U.S.

Analysis: Everyone expects the Fed to hold rates in October. Kevin Warsh could surprise us all · CNBC Markets
Kimberly-Clark is having its best week in four years. Here's what is propelling shares higher · CNBC Top News
Italy’s air traffic now fully restored after a network disruption led to 50% less planes in the sky · Fortune
Qatar will help revive Lebanon’s economy by fixing its power grid and rebuilding the war-damaged south, prime minister said · Fortune
Elon Musk spent $158 million on GOP leadership. Dem candidate James Talarico says rallygoers are ‘my slingshot’ against the ‘Goliaths’ to win Texas · Fortune
Warsh offers no fresh signals on interest rates · The Hill
E.l.f. Beauty CFO Mandy Fields on consumers, pricing and building a foundation in cosmetics · CNBC Top News
5 Moody Gothic Victorian Homes You Can Buy for Under $500K Right Now · Realtor.com News

All finance → · the U.S. local news →

Open HeyHomees →